3-Methylbutanoic Acid

3-Methylbutanoic Acid

SCHEMBL627178

CC(C)CC(=O)O.CCCCCC

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 11/20 0.56
AKR1B1 P15121 1/20 0.52
PPARG P37231 7/20 0.50
PPARD Q03181 7/20 0.50
PPARA Q07869 7/20 0.50
HDAC11 Q96DB2 5/20 0.50
TSHR P16473 4/20 0.50
PTPN1 P18031 3/20 0.50
ALDH1A1 P00352 2/20 0.50
TLR2 O60603 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
FABP4 P15090 2/20 0.50
SLC22A6 Q4U2R8 1/20 0.50
SLC22A8 Q8TCC7 1/20 0.50
MEN1 O00255 1/20 0.50
ESR1 P03372 1/20 0.50
ALOX15 P16050 1/20 0.50
PDE4A P27815 1/20 0.50
KMT2A Q03164 1/20 0.50
PDE3A Q14432 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Octane SCHEMBL2717632 0.97 GPR84 (0.59) GPR84AKR1B1PPARGPPARDPPARA
3-Methylbutanoic Acid SCHEMBL503119 0.97 GPR84 (0.59) GPR84AKR1B1PPARGPPARDPPARA
Hexadecane SCHEMBL27840691 0.97 GPR84 (0.59) GPR84AKR1B1PPARGPPARDPPARA
Hexanoate SCHEMBL7904664 0.91 AKR1B1 (0.70) GPR84AKR1B1PPARGPPARDPPARA
3-Methylbutanoic Acid SCHEMBL2303256 0.89 TDP1 (0.48) GPR84ALDH1A1TDP1SLC22A6
Octanoic Acid SCHEMBL15528089 0.89 GPR84 (0.71) GPR84AKR1B1PPARGPPARDPPARA
Nonanoate SCHEMBL15527828 0.89 GPR84 (0.71) GPR84AKR1B1PPARGPPARDPPARA
Decanoic Acid SCHEMBL15528050 0.89 GPR84 (0.71) GPR84AKR1B1PPARGPPARDPPARA
Undecanoate SCHEMBL15528113 0.89 GPR84 (0.71) GPR84AKR1B1PPARGPPARDPPARA
3-Methylbutanoic Acid SCHEMBL28019449 0.89 TSHR (0.54) GPR84PPARGPPARDPPARAHDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2603500-B1 INHIBITORS OF BRUTON'S TYROSINE KINASE HOFFMANN LA ROCHE (CH) 2014-11-19 EP disclosed
EP-2603500-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F.HOFFMANN-LA ROCHE AG (CH) 2013-06-19 EP disclosed
WO-2012020008-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F. HOFFMANN-LA ROCHE AG (CH) 2012-02-16 WO disclosed
EP-1023266-B1 PROCESS FOR MAKING DIARYL PYRIDINES USEFUL AS COX-2 INHIBITORS MERCK & CO INC (US) 2003-01-08 EP disclosed
US-20020042375-A1 Method of treating cancer HEIMBROOK DAVID C (US) 2002-04-11 US disclosed
EP-1023266-A2 PROCESS FOR MAKING DIARYL PYRIDINES USEFUL AS COX-2 INHIBITORS Merck & Co., Inc. (US) 2000-08-02 EP disclosed
US-6040450-A REACTING BENZOSULFIDE DERIVATIVE WITH MAGNESIUM TO FORM A MAGNESIUM HALIDE CONTAINING BENZOSULFIDE DERIVATIVE, REACTING THE INTERMEDIATE WITH PYRIDINE DERIVATIVE TO FORM INTERMEDIATE, OXIDIZING AND CONDENSING THE INTERMEDIATE MERCK & CO., INC. (US) 2000-03-21 US disclosed
WO-1999015503-A2 PROCESS FOR MAKING DIARYL PYRIDINES USEFUL AS COX-2 INHIBITORS MERCK & CO., INC. (US) 1999-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042375-A1 Method of treating cancer ACP3, KLK3, FOLH1 GPR84 3362/4885AKR1B1 425/4885PPARG 419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.